Shapiro gave third mRNA boosters to 88 cancer patients including 57 with hematologic cancers and observed decreased anti-spike IgG for hematologic cancer patients (particularly B cell malignancies and those receiving anti-CD20 antibody or BTK inhibitor.14 Again, our data matched with lower immune responses in our B cell malignancy cohorts. Here, BTK is linked to hematopoietic and lymphoid cell neoplasm.